Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sFlt1 ATAC
- Development stage
- Preclinical
- Lead developer
- Avilar Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
sFlt1 ATAC is an investigational heterobifunctional protein degrader developed by Avilar Therapeutics for the treatment of preeclampsia. It is part of the company's ATAC (ASGPR-Targeted Protein Degrader) platform, which is designed to degrade extracellular proteins. In preeclampsia, the protein soluble fms-like tyrosine kinase-1 (sFlt1) is overexpressed and released into the maternal circulation, where it antagonizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), leading to systemic endothelial dysfunction and hypertension. sFlt1 ATAC is designed to bind to circulating sFlt1 and the asialoglycoprotein receptor (ASGPR) on the surface of hepatocytes, facilitating the internalization and subsequent lysosomal degradation of sFlt1. This reduction in sFlt1 levels is intended to restore angiogenic balance and alleviate the symptoms of preeclampsia. The drug is administered via intravenous (IV) injection.
- Other names
- sFlt1-ATACsFlt-1-ATACsFlt 1-ATACsFlt1 heterobifunctional protein degradersFlt-1 heterobifunctional protein degradersFlt 1 heterobifunctional protein degrader
02
Targets
sFlt-1 (Soluble VEGFR-1)ASGPR (Asialoglycoprotein Receptor 1)
Beyond the preview
Go deeper on sFlt1 ATAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sFlt1 ATAC.